Full Transcript: GMR Solutions Q1 2026 Earnings Call - GMR Solutions (NYSE:GMRS)
GMR Solutions (NYSE:GMRS) reported Q1 2026 revenue of $1.46 billion (+6.6% YoY) and adjusted EBITDA of $305 million (+9.7%). The company said its recent IPO leaves net leverage around 3.5x. It cited a 47% rise in 911 nurse navigation calls and nearly $47 million in incremental annualized revenue from new agreements. 2026 guidance targets $5.89–$6.18 billion revenue and high single-digit adjusted EBITDA growth.
How this was made
The 30-second read
Why it matters
Key drivers for trading are the 2026 revenue/EBITDA guidance range, incremental annualized revenue from new agreements (~$47M), and management’s estimate of a CMS rule-change negative impact (<$5M annually).
Market read
Guidance and quantified policy impact are the main catalysts; incremental agreements and same-market growth support the bull case.
What to watch
Fuel/jet procurement mechanics and ACA-related volume assumptions were discussed but not fully quantified in the excerpt; traders may need to verify how these flow through margins and future quarters.
Background
The transcript covers GMR Solutions’ Q1 2026 performance, post-IPO leverage position, growth initiatives (911 nurse navigation), and reimbursement/regulatory updates (ACA, Medicaid supplemental payments, IDR process).
Ticker impact
GMR Solutions reported Q1 2026 results and issued 2026 revenue/EBITDA guidance, plus quantified CMS/Medicaid rule-change impacts.
Bias toward near-term upside as guidance and incremental revenue agreements were highlighted, with limited quantified regulatory downside.
The article includes concrete datapoints (Q1 revenue/EBITDA, net leverage ~3.5x post-IPO, 2026 guidance range, and CMS rule-change estimate), which typically drive repricing around earnings/guidance.
Market effects
CMS Medicaid supplemental payment reform and IDR process changes are discussed as relevant to emergency transport/air ambulance economics, a read-across for EMS/air ambulance operators.
Primarily US healthcare reimbursement dynamics (Medicaid/ACA/IDR) rather than region-specific demand shocks.
Limited; impacts are US policy/reimbursement driven.
Counterpoint
Even with a < $5M annual CMS headwind estimate, reimbursement-policy uncertainty could still widen spreads versus peers if assumptions prove optimistic.
Key entities
- public_companyGMR Solutions
Subject of the earnings call; provided Q1 results, post-IPO leverage, and 2026 guidance plus quantified regulatory impact.
- regulatorCMS
Discussed as expanding Medicaid supplemental payment reform and finalizing IDR operational changes affecting emergency transport/air ambulance.